CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2010-11-17): Sorafenib added to doxorubicin prolongs survival in advanced liver cancer

Clinical

Sorafenib added to doxorubicin prolongs survival in advanced liver cancer

Last Updated: 2010-11-17 14:25:05 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Combining the multikinase inhibitor sorafenib (Nexavar, Bayer) with doxorubicin improved overall and progression-free survival in patients with advanced hepatocellular carcinoma (HCC) in a phase 2 trial.

In fact, an interim analysis showed such benefit from combination treatment compared with doxorubicin monotherapy that the multinational trial was halted early, researchers led by Dr. Ghassan K. Abou-Alfa report in the November 17th issue of the Journal of the American Medical Association.

The 96 trial subjects had inoperable HCC with an Eastern Cooperative Oncology Group performance status of 0 to 2, Child-Pugh A status, and no prior systemic therapy. They were enrolled between April 2005 and October 2006, with the last follow-up in April 2008.

Dr. Abou-Alfa, from the Memorial Sloan-Kettering Cancer Center, New York, and his colleagues treated all patients with intravenous doxorubicin 60 mg/m� every 3 weeks for a maximum dose of 450 mg/m�. They randomly assigned them to additional treatment with sorafenib 400 mg (n = 47) or placebo (n = 49) twice daily, which were continued until disease progression.

Median time to disease progression was 6.4 months in the doxorubicin plus sorafenib group and 2.8 months in the doxorubicin plus placebo group (hazard ratio 0.5, p = 0.02).

Twenty-five patients in the sorafenib group and 38 in the placebo group died. Median overall survival was 13.7 months and 6.5 months, respectively (HR 0.49, p = 0.006).

The authors note that tumor shrinkage occurred in 62% of patients treated with sorafenib and in 29% of those treated with placebo.

"Adverse effects of doxorubicin plus sorafenib were essentially additive and similar to what would be expected for each drug used as a single agent," they report.

Based on these results, the authors have already started a phase 3 trial of sorafenib plus doxorubicin vs. sorafenib alone.

Sorafenib is approved in the US and Europe for treatment of liver cancer, although the authors note that "the combination of sorafenib and doxorubicin is not yet indicated for routine clinical use." Average cost of doxorubicin in the US is $143 for 200 mg. Sorafenib runs $7,863 for 120 200-mg tablets.

The study was supported by a research grant from Bayer, which also contributed to the study's design, conduct, and data collection.

SOURCE: http://link.reuters.com/qup75q

JAMA 2010;304:2154-2160.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.